Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
1.710
+0.080 (4.91%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty.
The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Mohamed Wa'el Hashad |
Contact Details
Address: Life Science & Technology Park, Suite 520 Miami, Florida 33136 United States | |
| Phone | 844 470 2550 |
| Website | longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L104 |
| ISIN Number | US54303L1044 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mohamed Wa'el Ahmed Hashad M.B.A. | Chief Executive Officer and Director |
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer and Chairman |
| Lisa A. Locklear M.B.A. | Chief Financial Officer, Executive Vice President and Treasurer |
| Paul T. Lehr J.D. | General Counsel and Secretary |
| Devin Blass | Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer |
| Lisa McClain-Moss | Vice President of Manufacturing |
| Brian G Rash Ph.D. | Vice President of Research and Discovery |
| Heather Zhou | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2025 | EFFECT | Notice of Effectiveness |
| Mar 28, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 14, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 10-K | Annual Report |
| Jan 30, 2025 | 8-K | Current Report |
| Nov 27, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |